Self Study 2024 Release I Bundle

Type: Bundle•Format: On-demand

The 2024 BCOP Self-Study Bundle Release I offers 9 BCOP CE hours and ACPE CE hours. All self-study modules are on-demand and allow you to complete your learning and claim your credits for up to one year following the release of the bundle.

This Self-Study Release I bundle contains the following modules:

  • Module 1: PARP Inhibitor Combination Regimens for Metastatic Castration-resistant Prostate Cancer (mCRPC) (2.50 BCOP/ACPE CE HOURS)
  • Module 2: Updates in Uveal Melanoma (2.50 BCOP/ACPE CE HOURS)
  • Module 3: Navigating Oncology Drug Shortages (2.00 BCOP/ACPE CE HOURS)
  • Module 4: Ocular Toxicities with Antineoplastics (2.00 BCOP/ACPE CE HOURS)

Get the bundle

Course Learning Objectives

UAN# 0465-0000-24-073-H01-P

Author: Bryan Fitzgerald, PharmD, BCOP

Learning Objectives

  1. Recognize the safety considerations of current PARP inhibitor + novel hormonal therapy combination regimens in the treatment of mCRPC
  2. Identify the most appropriate patient populations where combination PARP inhibitor + novel hormonal therapy regimens have shown clinical benefit
  3. Evaluate primary literature supporting the use of these combination regimens
  4. Develop appropriate treatment and supportive care plans utilizing PARP inhibitor combination therapy for patients with mCRPC with homologous recombination repair (HRR) gene alterations

UAN# 0465-0000-24-074-H01-P

Author: Christine Barrett, PharmD, BCOP

Learning Objectives

  1. Recall the differences in biology, prognosis, and treatment of uveal melanoma in comparison to cutaneous melanoma
  2. Review the safety and efficacy data for tebentafusp-tebn in metastatic uveal melanoma
  3. Describe treatment considerations for tebentafusp-tebn, including administration and toxicity management
  4. Identify the efficacy and safety data of immunotherapy in metastatic uveal melanoma

UAN#: 0465-0000-24-075-H04-P

Author: Joshua J. Elder, PharmD, BCPS, BCOP

Learning Objectives

  1. Describe negative consequences of oncology related drug shortages in the healthcare system
  2. Summarize strategies to proactively plan for possible drug shortages in the oncology setting
  3. Prepare responses for current drug shortages in the oncology setting to minimize impact to patient care
  4. Apply approaches to maintain equity when navigating oncology drug shortages

UAN# 0465-0000-24-076-H01-P

Author: Brandon Chang, PharmD, APh, BCPS, BCOP

Learning Objectives

  1. Recognize common and serious ocular adverse events associated with antineoplastics
  2. Describe the incidence of ocular toxicities for patients treated with targeted therapies and immune checkpoint inhibitors
  3. Compare the various strategies to prevent and manage ocular toxicities from antibody-drug conjugates
  4. Analyze efficacy and toxicity of the novel folate receptor alpha directed antibody-drug conjugate, mirvetuximab soravtansine

Knowledge Courses for Pharmacists

Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

acpe-bps-logos

HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post- Test with a 75% or higher.

All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.